73 related articles for article (PubMed ID: 21852056)
21. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
22. Obtaining blood samples for anti-factor Xa quantification through umbilical artery catheters.
Edstrom CS; McBride J; Theriaque D; Kao KJ; Christensen RD
J Perinatol; 2002 Sep; 22(6):475-7. PubMed ID: 12168126
[TBL] [Abstract][Full Text] [Related]
23. A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy.
Harris LF; Rainey P; Castro-López V; O'Donnell JS; Killard AJ
Analyst; 2013 Sep; 138(17):4769-76. PubMed ID: 23666610
[TBL] [Abstract][Full Text] [Related]
24. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
25. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
26. [Effect of unfractionated and low-molecular-weight heparin on platelet aggregation and in vitro bleeding time in dogs].
Nimmerfall K; Mischke R
Dtsch Tierarztl Wochenschr; 1999 Oct; 106(10):439-44. PubMed ID: 10589154
[TBL] [Abstract][Full Text] [Related]
27. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
28. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO.
Khaja WA; Bilen O; Lukner RB; Edwards R; Teruya J
Am J Clin Pathol; 2010 Dec; 134(6):950-4. PubMed ID: 21088159
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy.
Ensom MH; Stephenson MD
J Soc Gynecol Investig; 2004 Sep; 11(6):377-83. PubMed ID: 15350250
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
Bendetowicz AV; Béguin S; Caplain H; Hemker HC
Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
[TBL] [Abstract][Full Text] [Related]
32. Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors.
Stuart M; Johnson L; Hanigan S; Pipe SW; Li SH
J Thromb Haemost; 2020 Jul; 18(7):1653-1660. PubMed ID: 32216028
[TBL] [Abstract][Full Text] [Related]
33. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood.
Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
Thromb Haemost; 1988 Dec; 60(3):377-81. PubMed ID: 2853458
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
37. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy.
Rosenberg AF; Zumberg M; Taylor L; LeClaire A; Harris N
J Pharm Pract; 2010 Jun; 23(3):210-6. PubMed ID: 21507816
[TBL] [Abstract][Full Text] [Related]
38. In vivo age dependency of unfractionated heparin in infants and children.
Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P
Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072
[TBL] [Abstract][Full Text] [Related]
39. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
[TBL] [Abstract][Full Text] [Related]
40. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]